| Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? | |
| | |
MedLine Citation:
|
PMID: 19133699 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Major depressive disorder affects a substantial percentage of the U.S. population, and can be highly debilitating. Selective serotonin reuptake inhibitors are commonly prescribed to treat depression, but may not be as effective for more severe or persistent depression. METHODS: The authors review data concerning the effects of corticosteroid synthesis inhibitors (CSIs) in the management of depressive disorders, present a hypothesis as to their possible mechanisms of action based on recent data suggesting synergistic effects of glucocorticoids on extrahypothalamic corticotropin-releasing hormone (CRH), and consider alternative hypotheses. Published reports evaluating the efficacy of CSIs in treating depression are reviewed and presented in light of recent findings regarding actions of glucocorticoids on the central CRH system. RESULTS: Results from open label and double-blind studies by several groups have indicated that CSIs may be efficacious or of adjunctive value in some patients with depression, including those refractory to other agents; however, there is a need for more controlled studies. Several lines of data suggest that the mechanism of action of these agents may not be solely a function of inhibition of adrenal cortisol production. CONCLUSIONS: The authors propose that CSIs may be efficacious in part by reducing glucocorticoid enhancement of CRH action in neurons of the central nucleus of the amygdala and other structures outside the endocrine hypothalamus. Possible effects of systemically administered CSIs on glucocorticoid receptor regulation, neuroactive steroids, and classical monoamine systems are also discussed. We conclude that available clinical data suggest a potential role for CSIs in the management of depressive disorders, especially major depression with psychotic features. |
| | |
Authors:
|
Mitchel A Kling; Victoria H Coleman; Jay Schulkin |
Related Documents
:
|
16005439 - Changes in hypothalamic-pituitary-adrenal axis measures after vagus nerve stimulation t... 12682449 - Glucocorticoids and acute lung injury. 3922959 - Use of biologic markers in a general hospital affective disorders program. 22353759 - Neurobehavioral effects of interferon-α in patients with hepatitis-c: symptom dimensio... 3786599 - Abnormal dexamethasone suppression test in daily chronic headache sufferers. 8388949 - Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheob... 16236859 - Effect of oral aminophylline on pulmonary function improvement and tolerability in diff... 21153699 - Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adj... 17342249 - Healing by gentle touch ameliorates stress and other symptoms in people suffering with ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Depression and anxiety Volume: 26 ISSN: 1520-6394 ISO Abbreviation: Depress Anxiety Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-07-07 Completed Date: 2009-11-23 Revised Date: 2013-05-06 |
Medline Journal Info:
|
Nlm Unique ID: 9708816 Medline TA: Depress Anxiety Country: United States |
Other Details:
|
Languages: eng Pagination: 641-9 Citation Subset: IM |
Affiliation:
|
Department of Clinical Translational Medicine, Wyeth Research, Collegeville, Pennsylvania, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Glands
/
metabolism Aminoglutethimide / pharmacology*, therapeutic use* Anti-Inflammatory Agents / pharmacology*, therapeutic use* Corticotropin-Releasing Hormone / drug effects*, metabolism* Depressive Disorder, Major / diagnosis, drug therapy*, psychology Double-Blind Method Glucocorticoids / antagonists & inhibitors*, biosynthesis* Humans Hydrocortisone / antagonists & inhibitors*, biosynthesis Hypothalamus / drug effects*, metabolism* Ketoconazole / pharmacology*, therapeutic use* Metyrapone / pharmacology*, therapeutic use* Mifepristone / pharmacology*, therapeutic use* Severity of Illness Index |
| Grant Support | |
ID/Acronym/Agency:
|
Z01 MH002659-15/MH/NIMH NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Glucocorticoids; 125-84-8/Aminoglutethimide; 50-23-7/Hydrocortisone; 54-36-4/Metyrapone; 65277-42-1/Ketoconazole; 84371-65-3/Mifepristone; 9015-71-8/Corticotropin-Releasing Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Posttraumatic neuroma of the radial nerve treated with an autogenous epineural conduit technique. A ...
Next Document: Anxiety sensitivity as a predictor of the clinical course of panic disorder: a 1-year follow-up stud...